For important risk and disclaimer information, Click Here.
 |
Gary Levy | Managing Director
|
 |
|
 |
(516) 457-0104
|
VVA | THE PROBLEM
Over 65M post-menopausal women in the U.S. – and growing by 1M/year
32M+ women affected by Genitourinary Syndrome of Menopause (GSM) also widely known as Vulvovaginal Atrophy (VVA)
Symptoms include chronic vaginal dryness, itching, pain, infections, and sexual dysfunction
VVA also severely affects women in breast cancer treatment or recovery
Condition is underdiagnosed due to stigma and lack of effective options
VVA | OUR SOLUTION
A NOVEL BOTANICAL FORMULATION WITH CLINICALLY PROVEN EFFICACY COMPARABLE TO ESTROGEN
- Non-hormonal, non-systemic, and free of estrogenic pathway interaction
- Repairs tissue, reduces inflammation, and restores vaginal health
- Topically applied; no systemic absorption; zero observed side effects
- Raising $6M in equity (excluding $1.5M already secured) to achieve FDA clearance, commercial readiness and market entry
VVA |
COMPETITIVE
ADVANTAGE
VVA | OUR
COMPETITIVE EDGE
VEIGE | EXPERIENCED
EXECUTIVE LEADERSHIP TEAM
Jonathan Kalman | CEO
- Serial entrepreneur, with track record of launching, building, and selling successful businesses
- Early investor and board member across early-stage technology companies with a focus on biopharma and medical devices
- Three successful M&A transactions to international corporations for amounts ranging from $70M to $1.1B
Dr. William Levine | CSO
- DDS degree with specialty training in Periodontics from Columbia University
- Founder of Izun Pharmaceuticals, a biopharmaceutical company
- specializing in Botanical-based Medicine
- Diplomate of the American Board of Periodontology
- Member of Scientific Board of companies focused on Robotic Surgery and Oral Diagnostic technologies
Les Kraus | CFO
- CPA with 40+ years of operational and financial experience covering industrial, retail and wholesale businesses
- Former CFO of Australia’s largest menswear retailer, managing two sale processes to private equity firms
Dr Amy Rosenbluh | Director of Production & Laboratory Manager
- Master’s degree from Harvard University and Ph.D. from Tel Aviv University, with post-doctoral fellowships at both Stanford University and the Weizmann Institute
- Vast experience in academic research and management, both in academia and in the private sector
SPECIFIC RISKS
- Failure to obtain FDA 510 (K) clearance
- Delay in product launch
- Inability to reach projected sales and revenue forecasts
- Entry into the market of another non-Estrogen product with similar efficacy Challenge of building top tier marketing team
- Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment
